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Abstract: The treatment of metastatic renal cell carcinoma (mRCC) has markedly improved 
over the last few years with the introduction of several targeted agents in clinical practice. 
Nevertheless, either primary or secondary resistance to inhibition of VEGF and mTOR pathways 
has limited the clinical benefit of these systemic treatments. Recently, a better understanding of 
the involvement of MET and its ligand HGF in many biological processes made this signaling 
pathway an attractive therapeutic target in oncology, particularly in mRCC. Herein, we review 
the development of cabozantinib, a recently approved inhibitor of multiple tyrosine kinase 
receptors, including MET, VEGFRs, and AXL, which has proven to increase progression-free 
survival and overall survival when compared to everolimus in mRCC patients who had pro-
gressed after VEGFR-targeted therapy. Finally, we discuss the potential role of cabozantinib 
within the current treatment landscape for mRCC.
Keywords: cabozantinib, XL-184, metastatic renal cell carcinoma, VEGF-inhibitor, c-Met, 
targeted therapy
Introduction
Renal cell carcinoma (RCC) accounts for ~330,000 cases diagnosed each year and 
140,000 deaths worldwide.1 Most cases are localized; however, one-third of patients 
present with an advanced disease at diagnosis and ~30% of subjects eventually 
develop metastatic disease after nephrectomy. The VHL protein plays a major role 
in RCC, being downregulated due to gene inactivation or epigenetic silencing. As a 
consequence, the hypoxia-inducible factors (HIFs) are stabilized and VEGF, MET, 
and AXL genes are upregulated.2,3 This effect on VEGF can explain the angiogenic 
drive of clear-cell RCC (ccRCC), and expression of MET or AXL can be associ-
ated with an invasive tumor phenotype and poor prognosis.3,4–6 Preclinical evidence 
also showed that MET and AXL upregulation in ccRCC can also occur in response 
to VEGFR tyrosine kinase inhibitor (TKI) therapies, underlying a potential role for 
MET and AXL in the development of secondary resistance. Moreover, overexpres-
sion of angiopoietin, FGF, MET, and HGF has been associated with the mechanisms 
of resistance to VEGF inhibitors.7–9 Therapeutic strategies for metastatic disease are 
mostly based on VEGF inhibitors such as sunitinib, pazopanib, bevacizumab, sorafenib, 
and axitinib and mTOR inhibitors, including temsirolimus and everolimus. Neverthe-
less, despite an impressive improvement of outcome with targeted agents, complete 
remissions are rarely achieved and either primary or secondary resistance eventually 
develops. In addition, cross talk between the MET and VEGFR pathways is involved 
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in tumor neoangiogenesis and progression but is implicated in 
the resistance to anti-VEGFR agents. The recently approved 
cabozantinib is able to target both the VEGF and c-Met 
pathways in order to overcome resistance to TKIs while 
maintaining VEGF inhibition. This review focused on the 
clinical development of this novel agent and the potential 
placement among other approved drugs to treat metastatic 
renal cell carcinoma (mRCC).
MET pathway and renal cancer
The MET proto-oncogene is located on chromosome 7q21–31 
and encodes a tyrosine kinase receptor. The MET RTK is 
expressed on the surface of epithelial and endothelial cells, 
where it can be bound specifically by its ligand, the HGF. 
HGF is an inactive serine protease analog that is produced 
in cells of mesenchymal origin. MET and HGF are involved 
in many physiological and pathological processes, such as 
fetal development, including liver, placenta and muscle 
formation, as well as in the nervous system development.10 
After birth, HGF–MET pathway appears to be activated in 
epithelial–mesenchymal transition, as well as in liver, renal, 
and skin regeneration. MET signaling is also involved in 
tumor growth, invasion, resistance to systemic treatments, 
and angiogenesis. Furthermore, it plays an important role in 
RCC where MET expression is associated with poor progno-
sis and higher Fuhrman grade as well as advanced disease.11 
The results of MET signaling pathway activated from sev-
eral mechanisms, including chromosomal rearrangement, 
germline or somatic mutations, gene amplification, MET 
protein overexpression, and increased HGF expression, or 
by alternate activation of other pathways affecting MET.12 
Moreover, MET along with VEGFR-2 plays a synergistic 
role in promoting tumor angiogenesis and metastatic pheno-
type. Mutations in the HGF and MET genes are associated 
with bilateral type I papillary renal carcinoma (pRCC) in 
hereditary pRCC syndrome that generally has a better prog-
nosis. Type I pRCC presents a higher expression of MET 
when compared with the type II subtype, which generally 
presents poor pathological features with a poorer prognosis.13 
The trisomy of chromosome 7 is a common occurrence in 
pRCC, and several activating missense mutations of the MET 
gene have been described, both in sporadic and hereditary 
forms.14 MET expression is significantly higher in both type 
I and type II pRCCs than in clear-cell histology, justify-
ing MET inhibitors as a therapeutic strategy in advanced 
pRCC.15,16 Moreover, mutations or loss of the VHL gene 
under hypoxic conditions lead to accumulation of HIFs: as a 
result, different HIF target genes are upregulated, including 
VEGF, PDGF, TGF-a, and MET. HGF signaling is increased 
by hypoxia; thus, MET pathway contributes to invasive phe-
notype of VHL-negative renal carcinoma. Recently, Ciamp-
orcero et al17 evaluated the impact of either monotherapy 
or combination strategies targeting the VEGF and MET 
pathways in ccRCC mice models. Sunitinib-sensitive and 
sunitinib-resistant models of human ccRCC patient-derived 
xenograft were used to test these drugs. Immunodeficient 
SCID male mice (eight per group) were implanted with high 
c-Met expressing 786-O tumor cells and treated with either 
a VEGFR TKI, axitinib (36 mg/kg, two times per day); a 
c-Met inhibitor, crizotinib (25 mg/kg, one time per day); or 
combination. This drug combination was further tested in a 
human ccRCC low c-Met expressing patient-derived xeno-
graft, RP-R-01, in both VEGF-targeted therapy-sensitive and 
therapy-resistant models. The antitumor effect in both models 
was increased with the combination therapy, independent of 
MET expression. It was concluded that combined VEGF and 
HGF–MET pathway blockade might improve the outcome 
of RCC patients. Similarly, Shojaei et al18 observed that the 
addition of an MET inhibitor was able to overcome sunitinib 
resistance in mouse models with increased HGF expression 
that was resistant to sunitinib.
Preclinical models of cabozantinib 
activity
Cabozantinib (XL-184) was designed and synthesized as 
an oral small inhibitor of multiple tyrosine kinase recep-
tors with activity toward VEGF (VEGFR-2) and Met and 
also RET, KIT, AXL, TIE2, and FLT3 (Fms-like tyrosine 
kinase), which are also involved in tumor pathogenesis.19,20 
Met and VEGFR-2 play a synergistic role in promoting 
tumor angiogenesis and metastatic spread and are over-
expressed in hypoxic condition. Moreover, KIT and RET 
inhibitions make XL184 clinically effective in medullary 
thyroid cancer (MTC).19 Hypoxic conditions due to VEGF 
pathway inhibition can induce c-Met expression, which 
may eventually promote tumor invasion, survival, and 
metastasis. Drugs targeting only VEGF and its recep-
tors can hence induce Met, leading to the development 
of angiogenesis and cancer progression. Cabozantinib 
inhibits both the receptor tyrosine kinases, thus hamper-
ing the overexpression of these factors and causing an 
increase in tumor cell death associated with a decreased 
vascularization as shown in an MDA-MB-231 breast cancer 
xenograft model.19 These antiangiogenic effects translated 
into a proapoptotic effect able to hamper tumor growth in 
xenograft cancer models, including breast, lung cancer, 
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and glioblastoma.21 Cabozantinib showed to play a role in 
bone metastasis models since HGF, MET, and VEGFRs 
are expressed on either osteoblasts or osteoclasts, regulat-
ing their proliferation, migration, and survival.22,23 Bone 
metastases from prostate cancer seem to overexpress MET 
as compared to soft tissue metastases,13 and preclinical 
xenograft prostate cancer models showed responses to 
cabozantinib in nude mice.24 Activity of cabozantinib in 
patients with bone metastases from RCC has been con-
firmed in a Phase III trial.25
Phase I development of 
cabozantinib
The Phase I study was a dose-escalation trial done on the 
patients with advanced solid tumors to evaluate primary 
end points such as safety, pharmacokinetics, and maximum 
tolerated dose, and secondary end points such as response 
evaluation criteria in solid tumors (RECIST), pharmacody-
namics, RET mutational studies, and biomarker analyses. 
A total of 85 patients were enrolled, including 37 patients 
with MTC and two with RCC (one pRCC and one ccRCC). 
Ten patients (29%) experienced partial response, and seven 
patients had unconfirmed response. Fifteen patients (41%) 
had a stable disease with a duration of at least 6 months.26 The 
adverse events (AEs) occurring with cabozantinib were the 
same as those with the other drugs targeting RTKs, including 
VEGFR-2, KIT, and RET. Following these results, a Phase Ib 
drug–drug interaction study was designed to evaluate safety, 
tolerability, and efficacy of cabozantinib in 25 mRCC patients 
treated with at least one or two prior lines of systemic therapy. 
Cabozantinib was administered in doses up to 140 mg daily, 
which was associated with a single dose of rosiglitazone at 
day 22. All the patients received at least one or two prior lines 
of therapy, with 68% of patients receiving two or more prior 
systemic agents and 32% receiving four or more prior lines 
of therapy, including anti-VEGF treatment (88%), mTOR 
inhibitor therapy (60%), and both agents (52%). The majority 
of patients (84%) were classified as intermediate risk group 
per Heng criteria; only 4% were in the favorable risk group, 
while 12% were in the poor risk group. Bone metastases 
were present in four patients (16%).18 Seven of these patients 
(28%) had an objective response, and 13 (52%) had stable 
disease as per the RECIST criteria. At a median follow-up of 
14.7 months (range 11.2–21.8 months), the median progres-
sion-free survival (PFS) was 12.9 months, while the overall 
survival (OS) was 15.0 months with a median follow-up of 
28.3 months (range 24.8–35.5 months; Table 1). Three out 
of four patients with bone metastases showed a response, 
and two received effective palliation of bone pain from 
treatment. The safety profile was similar to other TKIs with 
grades 3–4 adverse AEs, including fatigue (16%), diarrhea 
(12%), hypophosphatemia (36%), and hyponatremia (20%).27 
Based on tolerability and activity associated with doses of 
cabozantinib ,140 mg in this study, a daily dose of 60 mg 
was selected for subsequent trials. These preliminary data 
have led to the design of randomized trials of cabozantinib in 
the first-line setting (NCT01835158)28 after development of 
resistance to a VEGFR TKI.25 More recently, positive results 
of both single-agent nivolumab, a novel monoclonal antibody 
that inhibits the interaction between PD-1 receptor expressed 
by activated T-cells and its ligand PD-L1 on the surface of 
tumor cells, which prevent T-cell activation (in the Phase III 
CheckMate-025 trial, where mRCC patients previously 
treated with at least one anti-VEGF treatment were randomly 
assigned to receive nivolumab or everolimus, the median 
OS was 5.4 months longer with nivolumab with an objec-
tive response rate (ORR) of 25% vs 5% for everolimus),29 
and cabozantinib (METEOR trial) in mRCC have provided 
the rationale for an ongoing Phase I combination trial of 
nivolumab and cabozantinib (NCT02496208).30
Phase II studies of cabozantinib
Cabozantinib has demonstrated clinical activity in different 
tumor types, including medullary and papillary thyroid can-
cers, melanoma breast cancer, lung cancer, ovarian cancer, 
hepatocellular carcinoma, and castration-resistant prostate 
cancer. In a Phase II randomized discontinuation study in 
men with castration-resistant prostate cancer (XL184-203), 
cabozantinib showed an increase in PFS as compared with 
placebo (median PFS 23.9 weeks vs 5.9 weeks).31 The ORR 
at 12 weeks was 5%, and the stable disease was reported 
in 75%. The majority of subjects (67%) achieved a bone 
Table 1 Summary of the published clinical trials and outcome measures for cabozantinib therapy
Study Description Patients (n) Primary end point OS Median PFS ORR
Shojaei et al18 Phase ib drug–drug interaction study 25 Safety and tolerability 15.0 months 12.9 months PR 28%
Choueiri et al16 Phase iii randomized on C vs e 658 PFS C 21.4 months
e 16.5 months
C 7.4 months
e 3.8 months
C: PR 21%
e: PR 5%
Abbreviations: OS, overall survival; PFS, progression-free survival; ORR, objective response rate; PR, partial response; C, cabozantinib; e, everolimus.
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scan response, including four patients showing a complete 
response and 62% with a partial response. Sixty-four percent 
of patients reported a 30% decrease in the average daily 
pain compared with baseline when considering patients 
with a baseline pain of at least 4 on a 0–10 scale. Disease 
control rates were also observed in other cohorts, including 
38% in non-small cell lung cancer, 48% in breast cancer, 
46% in melanoma, 47% in ovarian cancer, and 66% in 
hepatocellular carcinoma. Based on the success of Phase 
Ib study on RCC, a randomized Phase II study comparing 
cabozantinib versus sunitinib in the first-line intermediate or 
poor risk mRCC patients (CABOSUN) is being conducted 
by Alliance for Clinical Trials in Oncology. The primary 
end point is PFS. The study met its enrollment target of 
150 patients, and the results are due to be released in late 
2016.32 Another randomized Phase II study is enrolling 
mRCC patients to receive multiple MET kinase inhibitors, 
including cabozantinib, crizotinib, volitinib, or sunitinib, in 
metastatic papillary renal carcinoma (PAPMET) with the 
primary end point of PFS.33
Pivotal Phase III study of 
cabozantinib in mRCC
Based on these encouraging results, a randomized, open-label, 
Phase III study comparing cabozantinib with everolimus in 
patients with mRCC progressing after VEGFR TKI therapy 
was conducted.16 In this study, 658 patients were randomized 
1:1 to receive 60 mg of cabozantinib or 10 mg of everolimus 
daily and stratified based on the number of prior VEGFR TKI 
therapies and the risk criteria of Memorial Sloan Kettering 
Cancer Center (MSKCC). No cross-over was allowed. 
The primary end point was PFS, and the secondary end 
points were OS and ORR. The median PFS was 7.4 months 
(95% confidence interval [CI] 5.6–9.1) in the cabozantinib 
arm and 3.08 months (95% CI 3.7–5.4) in the everolimus 
arm with a rate of disease progression or death of 42% lower 
with cabozantinib (HR 0.58, 95% CI 0.45–0.75, P,0.001). 
In a post hoc analysis, the median PFS was 9.1 months 
(95% CI 5.6–11.2) with cabozantinib and 3.7 months (95% 
CI 1.9–4.2) with everolimus in a subgroup of patients who 
received sunitinib as their only prior systemic anti-VEGF 
treatment. The overall response rate was 21% with cabo-
zantinib as compared to 5% with everolimus. Stable disease 
occurred as the best response in 62% of patients in each 
group, while progressive disease occurred in 14% of patients 
treated with cabozantinib and 27% of patients treated with 
everolimus. At the prespecified interim analysis of OS, a 
trend toward longer OS with cabozantinib was observed, 
but the second interim analysis crossed the boundary for 
declaration of statistical significance for OS. The median OS 
was 21.4 months for patients receiving cabozantinib versus 
16.5 months for those receiving everolimus (HR =0.66, 
95% CI 0.53–0.83, P=0.0003) with a 34% reduction in the 
rate of death (Table 1).
Safety and tolerability
Most frequently reported grade 3 AEs in the Phase Ib study 
were fatigue (20%), diarrhea (12%), hypophosphatemia 
(40%), and hyponatremia (20%). Other grade 3 AEs reported 
included decreased appetite (4%), palmar-plantar erythrodys-
esthesia (PPE; 4%), hypertension (4%), and vomiting (4%). 
Fatigue (16%) and diarrhea were the most common relevant 
AEs noted with cabozantinib along with electrolyte abnor-
malities, including hypophosphatemia (36%) and hypona-
tremia (20%), in patients treated in the Phase II renal cancer 
trial. The dose used in the renal cancer trial was 140 mg daily; 
however, a number of toxicities were dose dependent. The 
frequency of drug discontinuation due to toxicities reported 
in the larger randomized discontinuation trial was 16%. 
A dose de-escalation study was conducted with continued 
assessment of efficacy in metastatic prostate cancer patients. 
The dose of 40 mg showed equivalent efficacy and lower 
toxicity, thus leading to the choice of the lower starting 
dose of 60 mg daily in the Phase III prostate cancer trials. In 
advanced renal cancer, a similar study should be conducted. 
In the Phase III METEOR trial, the most common AEs of 
any grade reported were diarrhea (74%), fatigue (56%), 
nausea (50%), decreased appetite (46%), and PPE (42%). 
The most common grades 3–4 AEs in the cabozantinib 
arm were hypertension (15%), diarrhea (11%), and fatigue 
(9%), while anemia (16%), hyperglycemia (5%), and fatigue 
(7%) were reported with everolimus. One patient in the 
cabozantinib group experienced a grade 5 treatment-related 
AE (death not otherwise specified). The most common AEs 
leading to dose reduction with cabozantinib were diarrhea 
(16%), PPE (11%), and fatigue (10%), while those with 
everolimus were pneumonitis (4%), stomatitis (3%), and 
fatigue (3%). Dose reduction occurred in 60% and 25% of 
patients treated with cabozantinib and everolimus, respec-
tively. Treatment discontinuation due to AEs occurred in 
9% of subjects receiving cabozantinib and in 10% of those 
receiving everolimus.16
Conclusion
Increasing evidence for the role of MET in the develop-
ment of resistance to anti-VEGF targeting agents led to the 
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development of cabozantinib as an orally bioavailable mul-
tikinase inhibitor that has shown a significant improvement 
in PFS and OS of patients with mRCC after failure of TKIs 
compared to everolimus. The drug has recently received the 
approval of the US Food and Drug Administration. Based 
on the information from the recently reported trial, its posi-
tion among other agents will be as a second-line therapy 
option for mRCC subjects progressing after at least one 
VEGF-TKI treatment. The overall PFS and that reported in 
patients receiving cabozantinib after sunitinib showed the 
best outcome for a single agent used for mRCC treatment. 
Besides, the PFS reported in the same study with everolimus 
was similar to that reported in the Phase III RECORD 1 
study.34 This supports the METEOR study that suggests that 
the characteristics of this study population may not be more 
favorable in comparison to previous studies. Significant side 
effects (diarrhea, fatigue, nausea, decreased appetite, PPE, 
and hypertension) have been observed with cabozantinib 
therapy, resulting in ~60% of patients undergoing a dose 
reduction in the Phase III trial versus everolimus. As a 
result, the management of the toxicity of patients receiving 
cabozantinib may be a potential key driver for treatment 
choice. Focusing on special populations such as patients with 
bone metastases from RCC would be a strategy to achieve 
improved efficacy in patients where currently approved drugs 
have shown less efficacy. Moreover, association studies are 
evaluating the effect of the combination of cabozantinib with 
checkpoint inhibitors in patients with mRCC.30 The ability 
of cabozantinib to cross the blood–brain barrier21 as shown 
in glioblastoma warrants investigation in mRCC. Targeting 
the MET and VEGFR pathways simultaneously represents 
a promising approach for RCC treatment since this will 
target multiple pathways. Cabozantinib has demonstrated 
an improvement in PFS, ORR, and OS of pretreated mRCC 
patients. The peculiar safety profile of cabozantinib requires 
a prompt management of AEs in order to minimize dose 
reduction and optimize outcome. Clinical trials to evaluate 
specific subpopulations such as patients with bone and brain 
metastases from mRCC need further evaluation.
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